Status:
COMPLETED
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Lead Sponsor:
Novartis
Collaborating Sponsors:
Novartis Vaccines
Conditions:
Meningococcal Infection
Eligibility:
All Genders
32-40 years
Phase:
PHASE4
Brief Summary
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Eligibility Criteria
Inclusion
- Healthy children
Exclusion
- known hypersensitivity to any vaccine component
- significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past 14 days
- ascertained or suspected disease caused by N. meningitidis
- household contact with or intimate exposure to an individual with a positive culture of N. meningitidis serogroup C within the previous 60 days
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
241 Patients enrolled
Trial Details
Trial ID
NCT00310635
Start Date
June 1 2005
Last Update
October 26 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mainz, Kehl, Traunreut, Mühldorf am Inn, Bad Sobernheim, Bad Kreuznach, Baldham, Speyer,
Oppenheim, Kempten, Germany